Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-HF
jRCT2061250038Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jun 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
01
Overview
Phase 3, randomised, double-blind trial of maridebart cafraglutide in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF) and obesity, sponsored by Amgen. Primary endpoint: Time to first occurrence of cardiovascular death or heart failure events. Started Jun 2025; status: recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on jRCT2061250038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250038.